Terms: = Head and neck cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
37 results:
1. Effects of a mucoadhesive phytomedicine (Curcuma longa L. and Bidens pilosa L.) on radiotherapy-induced oral mucositis and quality of life of patients undergoing head and neck cancer treatment: randomized clinical trial.
Martins AFL; Pereira CH; Morais MO; de Sousa-Neto SS; Valadares MC; Freitas NMA; Leles CR; de Mendonça EF
Support Care Cancer; 2023 Aug; 31(9):517. PubMed ID: 37566179
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
Wang L; Liu D; Wei D
Comput Math Methods Med; 2022; 2022():5145549. PubMed ID: 36060662
[TBL] [Abstract] [Full Text] [Related]
3. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
4. The Yin and Yang of erbb4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
5. Systems biomarkers for papillary thyroid cancer prognosis and treatment through multi-omics networks.
Gulfidan G; Soylu M; Demirel D; Erdonmez HBC; Beklen H; Ozbek Sarica P; Arga KY; Turanli B
Arch Biochem Biophys; 2022 Jan; 715():109085. PubMed ID: 34800440
[TBL] [Abstract] [Full Text] [Related]
6. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract] [Full Text] [Related]
7. Integrated miRNA and mRNA expression analysis uncovers drug targets in laryngeal squamous cell carcinoma patients.
Lapa RML; Barros-Filho MC; Marchi FA; Domingues MAC; de Carvalho GB; Drigo SA; Kowalski LP; Rogatto SR
Oral Oncol; 2019 Jun; 93():76-84. PubMed ID: 31109699
[TBL] [Abstract] [Full Text] [Related]
8. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
Yan T; Cui H; Zhou Y; Yang B; Kong P; Zhang Y; Liu Y; Wang B; Cheng Y; Li J; Guo S; Xu E; Liu H; Cheng C; Zhang L; Chen L; Zhuang X; Qian Y; Yang J; Ma Y; Li H; Wang F; Liu J; Liu X; Su D; Wang Y; Sun R; Guo S; Li Y; Cheng X; Liu Z; Zhan Q; Cui Y
Nat Commun; 2019 Apr; 10(1):1670. PubMed ID: 30975989
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
[TBL] [Abstract] [Full Text] [Related]
10. Simultaneous targeting of EGFR, HER2, and her4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
[TBL] [Abstract] [Full Text] [Related]
12. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
[TBL] [Abstract] [Full Text] [Related]
13. Pan-HER Inhibitor Augments Radiation Response in Human Lung and head and neck cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract] [Full Text] [Related]
14. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
[TBL] [Abstract] [Full Text] [Related]
15. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and head and neck cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract] [Full Text] [Related]
16. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
Martinez-Useros J; Garcia-Foncillas J
Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
[TBL] [Abstract] [Full Text] [Related]
17. erbb4 as a potential molecular target in the treatment of esophageal squamous cell cancers.
Zhao K; Chen BJ; Chen ZG
ScientificWorldJournal; 2014; 2014():124105. PubMed ID: 25538945
[TBL] [Abstract] [Full Text] [Related]
18. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract] [Full Text] [Related]
19. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
[TBL] [Abstract] [Full Text] [Related]
20. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
Ohnishi Y; Minamino Y; Kakudo K; Nozaki M
Oncol Rep; 2014 Aug; 32(2):780-6. PubMed ID: 24926885
[TBL] [Abstract] [Full Text] [Related]
[Next]
